Disclaimer
For health care professionals in EUROPE excepted those practicing in France as the following pages are intended to all International health care professionals and are not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011 article 34. Other health care professionals should select their country in the top right corner of the website.
Please note that the following pages are exclusively reserved for health care professionals in countries with applicable health authority product registrations. To the extent this site contains information, reference guides and databases intended for use by licensed medical professionals, such materials are not intended to offer professional medical advice. Prior to use, please consult device labeling for prescriptive information and operating instructions.
This Website is protected by the laws on copyright and by the relevant international conventions. It is strictly forbidden to make copies, whether partial or total and on whichever media without prior approval.
Get Informed About the WATCHMAN FLXTM Implant Procedure
MINIMALLY INVASIVE
PERMANENT IMPLANT
TYPICAL PROCEDURE IS LESS THAN 1 HOUR
24 HOUR AVERAGE HOSPITAL STAY
1
Using a standard percutaneous technique, a guidewire and vessel dilator are inserted into the femoral vein.
2
The implant procedure is performed with fluoroscopy and transesophageal echocardiography (TEE). The interatrial septum is crossed using a standard transseptal access system.
3
The access sheath is advanced over the guidewire into the left atrium and then navigated into the distal portion of the LAA over a pigtail catheter.
4
WATCHMAN FLX is then deployed and released in the LAA.
5
Heart tissue grows over the WATCHMAN FLX Implant and the LAA is permanently sealed.
6
A fully endothelialized device
Post-Implant Drug Regimen
Post-implant medication is at the the discretion of each physician and is subject to the patient's specific condition and medical history. Boston Scientific does provide general guidelines in the instructions for use (IFU) of the device, based on the robust clinical results observed in the RCTs and the EWOLUTION registry.
WATCHMAN FLX post-implant drug regimen
REFERENCES
* Implant success defined as deployment and release of the device into the LAA; no leak ≥ 5 mm
1. Boersma LVA et al. Implant Success and Safety of Left device: periprocedural outcomes from the EWOLUTION Registry. Eur Heart J 2016;37(31):2465-74.
2. INTERIM POST-MARKET SURVEILLANCE STUDY REPORT on EWOLUTION May 5, 2017
CAUTION:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device.
Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries.
This material not intended for use in France.